Last reviewed · How we verify

NCT07104435

Community Recreation to Enhance Function in Aging

Active, enrolled NA Last updated 22 October 2025
What this trial tests

NA trial testing Artmaking and exergaming in Physical Functional Impairment in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
12 September 2025
Primary endpoint
11 May 2026
15 June 2026

Quick facts

Lead sponsorState University of New York at Buffalo
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment80
Start date12 September 2025
Primary completion11 May 2026
Estimated completion15 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

State University of New York at Buffalo

Who can join

60 and older, any sex, with Physical Functional Impairment or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This aim of this study is to examine the therapeutic impacts of a group-based recreational program that delivers guided visual artmaking and dual-task exergaming, to older adults. Outcomes of interest include cognitive function (attention, task-switching, interference inhibition), physical function (balance, walking, lower-limb strength), and dual-task performance. Key implementation outcomes including intervention fidelity, feasibility, and acceptability will be explored to inform design of future community-based intervention programs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other State University of New York at Buffalo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing